5 insiders reported 10 Form 4 transactions for aTYR PHARMA INC (ATYR) over the past 18 months (most recent 2026-05-28). Recent activity: SCHIMMEL PAUL (Director) Buy 100,000 shares, Shukla Sanjay (President and CEO) Buy 10,375 shares, DENYES NANCY (General Counsel) Buy 2,687 shares, DENYES NANCY (General Counsel) Sell 1,118 shares, Broadfoot Jill Marie (Chief Financial Officer) Buy 3,750 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-28 | SCHIMMEL PAUL | Director | Buy | 100,000 | $49,630 |
| 2026-02-04 | Shukla Sanjay | President and CEO | Buy | 10,375 | $0 |
| 2026-02-04 | DENYES NANCY | General Counsel | Buy | 2,687 | $0 |
| 2026-02-04 | DENYES NANCY | General Counsel | Sell | 1,118 | $1,096 |
| 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Buy | 3,750 | $0 |
| 2026-02-04 | Broadfoot Jill Marie | Chief Financial Officer | Sell | 1,558 | $1,527 |
| 2026-02-04 | Shukla Sanjay | President and CEO | Sell | 3,745 | $3,670 |
| 2025-10-09 | SCHIMMEL PAUL | Director | Buy | 682,001 | $613,801 |
| 2025-10-09 | SCHIMMEL PAUL | Director | Buy | 317,999 | $298,919 |
| 2025-03-17 | Gross Jane A | Director | Buy | 3,750 | $15,000 |
Source: SEC Form 4 filings · as of 2026-05-28